High-quality trial(s) have failed to demonstrate the claimed effect, or known harms outweigh the marketed benefit.
| # | Compound | Category | EU Status | Last reviewed |
|---|---|---|---|---|
| 001. | Melanotan II C₅₀H₆₉N₁₅O₉ · MW 1024.2 Cyclic heptapeptide · non-selective melanocortin receptor agonist | Hormonal | PROHIBITED | 18 MAY 2026 |